Literature DB >> 18836136

c-Jun N-terminal kinase 1 is required for the development of pulmonary fibrosis.

John F Alcorn1, Jos van der Velden, Amy L Brown, Brian McElhinney, Charles G Irvin, Yvonne M W Janssen-Heininger.   

Abstract

Collagen deposition is observed in a diverse set of pulmonary diseases, and the unraveling of the molecular signaling pathways that facilitate collagen deposition represents an ongoing area of investigation. The stress-activated protein kinase, c-Jun N-terminal kinase 1 (JNK1), is activated by a large variety of cellular stresses and environmental insults. Recent work from our laboratory demonstrated the critical role of JNK1 in epithelial to mesenchymal transition. The goal of the present study was to examine the involvement of JNK1 in subepithelial collagen deposition in mice subjected to models of allergic airways disease and interstitial pulmonary fibrosis. Activation of JNK was slightly enhanced in lungs from mice subjected to sensitization and challenge with ovalbumin (Ova), and predominant localization of phospho-JNK was observed in the bronchial epithelium. While mice lacking JNK1 (JNK1-/- mice) displayed enhanced lung inflammation and cytokine production compared with wild-type (WT) mice, JNK1-/- mice accumulated less subepithelial collagen deposition in response to antigen, and showed decreased expression of profibrotic genes compared with WT animals. Furthermore, transforming growth factor (TGF)-beta1 content in the bronchoalveolar lavage was diminished in JNK1-/- mice compared with WT animals subjected to antigen. Finally, we demonstrated that mice lacking JNK1 were protected against TGF-beta1 and bleomycin-induced pro-fibrotic gene expression and pulmonary fibrosis. Collectively, these findings demonstrate an important requirement for JNK1 in promoting collagen deposition in multiple models of fibrosis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18836136      PMCID: PMC2660560          DOI: 10.1165/rcmb.2008-0174OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  72 in total

1.  Dual-immunohistochemistry provides little evidence for epithelial-mesenchymal transition in pulmonary fibrosis.

Authors:  Mizuho Yamada; Kazuyoshi Kuwano; Takashige Maeyama; Naoki Hamada; Michihiro Yoshimi; Yoichi Nakanishi; Michael Kasper
Journal:  Histochem Cell Biol       Date:  2008-01-31       Impact factor: 4.304

2.  Localisation of transforming growth factor beta1 and beta3 mRNA transcripts in normal and fibrotic human lung.

Authors:  R K Coker; G J Laurent; P K Jeffery; R M du Bois; C M Black; R J McAnulty
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

3.  Activation of the TGF-beta/activin-Smad2 pathway during allergic airway inflammation.

Authors:  A Rosendahl; D Checchin; T E Fehniger; P ten Dijke; C H Heldin; P Sideras
Journal:  Am J Respir Cell Mol Biol       Date:  2001-07       Impact factor: 6.914

4.  TGF-beta1 activates MAP kinase in human mesangial cells: a possible role in collagen expression.

Authors:  T Hayashida; A C Poncelet; S C Hubchak; H W Schnaper
Journal:  Kidney Int       Date:  1999-11       Impact factor: 10.612

5.  Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts.

Authors:  E Piek; W J Ju; J Heyer; D Escalante-Alcalde; C L Stewart; M Weinstein; C Deng; R Kucherlapati; E P Bottinger; A B Roberts
Journal:  J Biol Chem       Date:  2001-03-21       Impact factor: 5.157

6.  Is Smad3 a major player in signal transduction pathways leading to fibrogenesis?

Authors:  A B Roberts; E Piek; E P Böttinger; G Ashcroft; J B Mitchell; K C Flanders
Journal:  Chest       Date:  2001-07       Impact factor: 9.410

7.  Jun N-terminal kinase 1 regulates epithelial-to-mesenchymal transition induced by TGF-beta1.

Authors:  John F Alcorn; Amy S Guala; Jos van der Velden; Brian McElhinney; Charles G Irvin; Roger J Davis; Yvonne M W Janssen-Heininger
Journal:  J Cell Sci       Date:  2008-03-11       Impact factor: 5.285

8.  Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction.

Authors:  L Boulet; M Bélanger; G Carrier
Journal:  Am J Respir Crit Care Med       Date:  1995-09       Impact factor: 21.405

9.  Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1.

Authors:  Robert Eferl; Peter Hasselblatt; Martina Rath; Helmut Popper; Rainer Zenz; Vukoslav Komnenovic; Maria-Helena Idarraga; Lukas Kenner; Erwin F Wagner
Journal:  Proc Natl Acad Sci U S A       Date:  2008-07-18       Impact factor: 11.205

10.  Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73.

Authors:  T Smeal; B Binetruy; D A Mercola; M Birrer; M Karin
Journal:  Nature       Date:  1991-12-12       Impact factor: 49.962

View more
  45 in total

1.  Salvianolic acid A attenuates kidney injury and inflammation by inhibiting NF-κB and p38 MAPK signaling pathways in 5/6 nephrectomized rats.

Authors:  Hong-Feng Zhang; Yan-Li Wang; Cheng Gao; Yan-Ting Gu; Jian Huang; Jin-Hui Wang; Jia-Hong Wang; Zhou Zhang
Journal:  Acta Pharmacol Sin       Date:  2018-05-23       Impact factor: 6.150

2.  Involvement of c-Jun N-Terminal Kinase in TNF-α-Driven Remodeling.

Authors:  Irene M J Eurlings; Niki L Reynaert; Cheryl van de Wetering; Scott W Aesif; Evi M Mercken; Rafael de Cabo; Jos L van der Velden; Yvonne M Janssen-Heininger; Emiel F M Wouters; Mieke A Dentener
Journal:  Am J Respir Cell Mol Biol       Date:  2017-03       Impact factor: 6.914

3.  The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.

Authors:  Lei Zhang; Jian-Bing Hao; Lian-Sheng Ren; Jiu-Li Ding; Li-Rong Hao
Journal:  Lab Invest       Date:  2014-05-26       Impact factor: 5.662

4.  Absence of c-Jun NH2-terminal kinase 1 protects against house dust mite-induced pulmonary remodeling but not airway hyperresponsiveness and inflammation.

Authors:  Jos L J van der Velden; Sidra M Hoffman; John F Alcorn; Jane E Tully; David G Chapman; Karolyn G Lahue; Amy S Guala; Lennart K A Lundblad; Minara Aliyeva; Nirav Daphtary; Charles G Irvin; Yvonne M W Janssen-Heininger
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-03-07       Impact factor: 5.464

5.  alpha2-antiplasmin is associated with the progression of fibrosis.

Authors:  Yosuke Kanno; Eri Kawashita; Misato Minamida; Aki Kaneiwa; Kiyotaka Okada; Shigeru Ueshima; Osamu Matsuo; Hiroyuki Matsuno
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

6.  Chitosan dressing promotes healing in third degree burns in mice: gene expression analysis shows biphasic effects for rapid tissue regeneration and decreased fibrotic signaling.

Authors:  Ruth M Baxter; Tianhong Dai; Jess Kimball; Eugenia Wang; Michael R Hamblin; William P Wiesmann; Simon J McCarthy; Shenda M Baker
Journal:  J Biomed Mater Res A       Date:  2012-07-30       Impact factor: 4.396

7.  Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition.

Authors:  Johannes Kluwe; Jean-Philippe Pradere; Geum-Youn Gwak; Ali Mencin; Samuele De Minicis; Christoph H Osterreicher; Jordi Colmenero; Ramon Bataller; Robert F Schwabe
Journal:  Gastroenterology       Date:  2009-09-24       Impact factor: 22.682

8.  A review of current and novel therapies for idiopathic pulmonary fibrosis.

Authors:  Rokhsara Rafii; Maya M Juarez; Timothy E Albertson; Andrew L Chan
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

9.  Foxm1 transcription factor is required for lung fibrosis and epithelial-to-mesenchymal transition.

Authors:  David Balli; Vladimir Ustiyan; Yufang Zhang; I-Ching Wang; Alex J Masino; Xiaomeng Ren; Jeffrey A Whitsett; Vladimir V Kalinichenko; Tanya V Kalin
Journal:  EMBO J       Date:  2013-01-04       Impact factor: 11.598

Review 10.  Dissecting fibrosis: therapeutic insights from the small-molecule toolbox.

Authors:  Carmel B Nanthakumar; Richard J D Hatley; Seble Lemma; Jack Gauldie; Richard P Marshall; Simon J F Macdonald
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.